Limberg JK, Johnson BD, Mozer MT, Holbein WW, Curry TB, Prabhakar NR, Joyner MJ. Role of the carotid chemoreceptors in insulin-mediated sympathoexcitation in humans. Am J Physiol Regul Integr Comp Physiol 318: R173–R181, 2020. First published November 20, 2019. doi:10.1152/ajpregu.00257.2019.
In the original article, there was an error in the unit used to describe plasma insulin levels. The unit has updated from mg/dL to μIU/mL. The revised sections are shown below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
In the results section, page R175, “plasma insulin: 7 ± 1 to 51 ± 2 mg/dL” should read as “plasma insulin: 7 ± 1 to 51 ± 2 μIU/mL.” The revised sentence is below.
Under control (saline) conditions (n = 18, protocols 1 and 2 pooled), intravenous insulin was infused at a constant rate (plasma insulin: 7 ± 1 to 51 ± 2 μIU/mL), during which time exogenous glucose was infused (glucose infusion rate: 28 ± 2 mL/h) to maintain euglycemia (94 ± 2 to 95 ± 2 mg/dL).
In the results section, page R176, “plasma insulin: saline 7 ± 1 to 46 ± 2 mg/dL; dopamine 13 ± 2 to 50 ± 4 mg/dL” should read as “plasma insulin: saline 7 ± 1 to 46 ± 2 μIU/mL; dopamine 13 ± 2 to 50 ± 4 μIU/mL.” The revised sentence is below.
On both visits insulin was infused at a constant rate (plasma insulin: 7 ± 1 to 46 ± 2 μIU/mL during the saline visit and 13 ± 2 to 50 ± 4 μIU/mL during the low-dose dopamine visit), and exogenous glucose was infused concomitantly (29 ± 3 mL/h during the saline visit and 29 ± 4 mL/h during the low-dose dopamine visit) to maintain blood glucose at fasted levels (93 ± 2 to 94 ± 2 mg/dL during the saline visit and 101 ± 3 to 101 ± 3 mg/dL during the low-dose dopamine visit).
In the Perspectives and Significance section of the discussion, page R179, “hyperinsulinemic range tested (∼50 mg/dL)” should read as “hyperinsulinemic range tested (∼50 μIU/mL).” The revised sentence is below.
Present data suggest the CB chemoreceptors are not necessary for the sympathoexcitatory response to steady-state insulin infusion in healthy humans in the hyperinsulinemic range tested (∼50 μIU/mL).